Rapport Therapeutics is a clinical-stage biotechnology company that has incurred significant financial losses since inception and expects to continue doing so. As of November 2, 2026, the company had 59,279,630 shares of common stock outstanding and is focused on developing its lead product candidate, RAP-219, for neurological disorders.
Rapport Therapeutics reported third quarter 2026 financial results and highlighted positive Phase 2 topline results for RAP-219 in bipolar mania. The company is well-capitalized with $815.4 million in cash following a recent financing, providing a projected runway through the end of 2029.
Term
Q3 2026
“Our positive Phase 2 results in bipolar mania are transformational for Rapport, accelerating our path to becoming an industry-leading precision neuroscience company. RAP-219 now has clinical proof-of-concept in two indications across neurology and psychiatry, giving us the opportunity to serve patients in two multibillion-dollar markets.”
Abraham N. Ceesay, chief executive officer of Rapport
Rapport Therapeutics Insider James Healy Buys $20.4M of Stock
James Healy bought 969,480 shares of Rapport Therapeutics, Inc. at $21.00 a share, worth $20.4M in total on Oct 28, 2026. Shares held after the trade: 25,267 (+37.8%).
Rapport Therapeutics entered into an underwriting agreement for a public offering of 8,333,334 shares of common stock and 1,190,476 pre-funded warrants at a price of $21.00 per share. The underwriters fully exercised their option to purchase an additional 1,428,571 shares, bringing estimated net proceeds to approximately $215.7 million. The funds are intended to support clinical trials for RAP-219 and other research and development activities.
Rapport Therapeutics CEO Abraham Ceesay Sells $64.4K of Stock
Abraham Ceesay, CEO, sold 2,210 shares of Rapport Therapeutics, Inc. at $29.16 a share, worth $64.4K in total on Oct 21, 2026. Shares held after the trade: 450,035 (-0.5%).
Rapport Therapeutics Director Ramiro Sanchez Buys $98.5K of Stock
Ramiro Sanchez, Director, bought 3,600 shares of Rapport Therapeutics, Inc. at $27.35 a share, worth $98.5K in total on Oct 23, 2026. Shares held after the trade: 3,600.
Rapport Therapeutics Director Paul M. Silva Buys $99.6K of Stock
Paul M. Silva, Director, bought 3,680 shares of Rapport Therapeutics, Inc. at $27.07 a share, worth $99.6K in total on Oct 22, 2026. Shares held after the trade: 3,680.
Rapport Therapeutics Director Wendy B. Young Buys $100K of Stock
Wendy B. Young, Director, bought 3,789 shares of Rapport Therapeutics, Inc. at $26.39 a share, worth $100K in total on Oct 22, 2026. Shares held after the trade: 13,289 (+39.9%).
Rapport Therapeutics Director Steven M. Paul Buys $974K of Stock
Steven M. Paul, Director, bought 35,714 shares of Rapport Therapeutics, Inc. at $27.28 a share, worth $974K in total on Oct 22, 2026. Shares held after the trade: 77,380 (+85.7%).
Rapport Therapeutics Director John Maraganore Buys $249K of Stock
John Maraganore, Director, bought 9,411 shares of Rapport Therapeutics, Inc. at $26.38 to $26.92 a share (average $26.45) in 2 transactions, worth $249K in total on Oct 22, 2026. Shares held after the trade: 9,411 (+14.2%).
Rapport Therapeutics CFO Troy A. Ignelzi Buys $144K of Stock
Troy A. Ignelzi, CFO, bought 5,500 shares of Rapport Therapeutics, Inc. at $26.10 a share, worth $144K in total on Oct 21, 2026. Shares held after the trade: 15,500 (+55.0%).
Rapport Therapeutics announced positive topline results from its Phase 2 trial of RAP-219 for the treatment of bipolar mania, meeting the primary endpoint with a statistically significant 3.1-point placebo-adjusted improvement in the YMRS total score. The drug was well-tolerated with no serious adverse events, establishing clinical proof-of-concept for its novel TARP g8-selective mechanism. The company plans to progress RAP-219 into Phase 3 trials for bipolar mania in the second half of 2027.
Rapport Therapeutics CEO Abraham Ceesay Sells $143K of Stock
Abraham Ceesay, CEO, sold 4,522 shares of Rapport Therapeutics, Inc. at $30.66 to $32.03 a share (average $31.68) in 2 transactions, worth $143K in total between Oct 6, 2026 and Oct 7, 2026. Shares held after the trade: 452,245 (-0.3%).
Rapport Therapeutics COO Cheryl Gault Sells $332K of Stock
Cheryl Gault, COO, sold 10,000 shares of Rapport Therapeutics, Inc. at $33.04 to $33.76 a share (average $33.19) in 2 transactions, worth $332K in total on Sep 30, 2026. Shares held after the trade: 139,914 (-1.5%).
Rapport Therapeutics CEO Abraham Ceesay Sells $76.2K of Stock
Abraham Ceesay, CEO, sold 1,952 shares of Rapport Therapeutics, Inc. at $39.05 a share, worth $76.2K in total on Sep 23, 2026. Shares held after the trade: 457,025 (-0.4%).